March 20, 2023
Fierce Biotech
Fierce Medtech’s 2022 Fierce 15
Focused on Changing Breast Cancer Outcomes
PreciseDx is dedicated to supporting more personalized and precise treatments for breast cancer.
On average, every two minutes a woman is diagnosed with breast cancer in the United States.
About 1 in 8 U.S. women (about 2.3 million diagnosed annually) will develop invasive breast cancer over the course of their lifetime.
About PreciseDx
PreciseDx is the only Cancer Risk Stratification company to provide patient-specific risk information through the analysis of morphology features, enabling better and more personalized treatment and outcomes. Clinical teams can rely on PreciseDx for unmatched insights and actionable intelligence in determining the best treatment for each patient.
Integrating artificial intelligence, lab processes and workflow systems
Transforming clinical modeling, patient phenotyping, and image analysis
Providing unmatched insights to support pathologists, and oncologists
Better Data. Better Outcomes.
PreciseDx’s AI-powered predictive platform creates disease-specific assays that deliver new levels of patient risk information to drive benefits across the healthcare continuum.
- Patients
- Providers
- Payers
- BioPharma
The PreciseDx platform enables individualized treatment plans and supports improved patient outcomes.
For providers, PreciseDx delivers highly accurate risk profiles, enables diagnostic precision, reduces error rates and decreases costs.
By providing accurate risk profiles for each individual patient, PreciseDx enables decreased costs for payers.
The PreciseDx AI platform is available for biopharmaceutical research and development, enabling researchers to leverage AI insights and data derived from high-volume, well-annotated study populations.
Patients
The PreciseDx platform enables individualized treatment plans and supports improved patient outcomes.
Providers
For providers, PreciseDx delivers highly accurate risk profiles, enables diagnostic precision, reduces error rates and decreases costs.
Payers
By providing accurate risk profiles for each individual patient, PreciseDx enables decreased costs for payers.
BioPharma
The PreciseDx AI platform is available for biopharmaceutical research and development, enabling researchers to leverage AI insights and data derived from high-volume, well-annotated study populations.
“PreciseDx has an opportunity to improve the quality for all patients through our digital platform. The level of patient-specific detail we can provide to oncologists and pathologists is unmatched, and our ability to provide this as a digital service means that we are not bound by location.”
Jack Zeineh, PreciseDx
“PreciseDx has an opportunity to improve the quality for all patients through our digital platform. The level of patient-specific detail we can provide to oncologists and pathologists is unmatched, and our ability to provide this as a digital service means that we are not bound by location.”
Featured Resources & Media
Media Coverage
Media Coverage
March 17, 2023
Fierce Healthcare
Biden’s ‘Cancer Moonshot’ is already being fueled by tech addressing breast cancer
Press Release
March 8, 2023
PR Newswire
PreciseDx to Present on AI-enabled Breast Cancer Grade and Phenotyping Assay at United States and Canadian Academy of Pathology (USCAP) Annual Meeting
Media Coverage
February 24, 2023
WSJ Pro: Venture Capital
Subsidiary of VC-Backed ElevateBio Draws Moderna’s Attention
Media Coverage
February 22, 2023
Diagnostics World
HemaChrome Wins the NIH’s RADx Tech for Maternal Health Challenge, Next-Generation Pathology Analysis Enriches Breast Cancer Grading, More
Media Coverage
February 22, 2023
ai TechPark
PreciseDx Appoints Bradley Gendell as Chief Financial Officer
Media Coverage
Media Coverage
March 17, 2023
Fierce Healthcare
Biden’s ‘Cancer Moonshot’ is already being fueled by tech addressing breast cancer
Press Release
March 8, 2023
PR Newswire
PreciseDx to Present on AI-enabled Breast Cancer Grade and Phenotyping Assay at United States and Canadian Academy of Pathology (USCAP) Annual Meeting